期刊文献+

K562细胞分泌的exosome的免疫电镜研究 被引量:4

Observation of K562 cell-secreted exosomes with immunoelectron microscope
下载PDF
导出
摘要 目的:通过免疫电镜方法观察K562细胞分泌的 exosome,探讨其潜在的临床应用价值.方法:采用离心超滤和 蔗糖密度梯度离心等方法分离出K562细胞释放的exosome, 经透射电镜观察其超微结构.采用固相免疫电镜法(SPIEM) 制备exosome的HSP70,ICAM 1及ABL免疫电镜标本.结果: K562细胞分泌的exosome为直径50~100nm的膜性微囊结 构,圆形或椭圆形,腔内为低电子密度成分.经抗HSP70, ICAM 1和ABL抗体 胶体金免疫电镜标记,囊外膜及腔内可 见点状、颗粒状电子致密物沉积.结论:离心超滤和蔗糖密度 梯度离心法纯化小量exosome方法可行,K562细胞分泌的ex osome表达HSP70,ICAM 1和ABL蛋白,具备免疫原性. AIM: To observe K562 cell-secreted exosomes under immunoelectron microscope and to discuss their potential clinical value. METHODS: Exosomes were purified by ultrafiltration centrifugation and sucrose gradient ultracentrifugation. Electron microscopy was used to observe their ultrastructures. The expression of HSP70, ICAM-1 and ABL were investigated by solid phase immunoelectron microscopic method (SPIEM). RESULTS: Transmission electron microscopy revealed that the exosomes from K562 cell culture supernatants were 50 to 100 nm membrane vesicles. They were round or ellipse in shape. Cavum had low electron-density components, which were labeled by colloidal gold HSP70, ICAM-1 and ABL. Immune electron microscopy showed the deposition of electron particles in the extramembrane and cavum of the vesicles. CONCLUSION: Ultrafiltration centrifugation and sucrose gradient ultracentrifugation can be used to purify K562 cells-secreted exosomes. The exosomes express HSP70, ICAM-1 and ABL protein and have immunogenicity.
出处 《第四军医大学学报》 北大核心 2005年第5期401-403,共3页 Journal of the Fourth Military Medical University
关键词 EXOSOMES K562细胞 超滤 免疫电镜 exosome K562 cell ultrafiltration immunoelectron microscope
  • 相关文献

参考文献6

  • 1Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming [J]. Nat Med, 2001;7(3):297-303.
  • 2Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function [J]. Nat Rev Immunol, 2002;2(5):569-579.
  • 3Henry GL, Anita MD, Sanjay P, et al. Production and characterization of clinical grade exosomes derived from dendritic cells [J]. J Immunol Methods, 2002; 270(2):211-226.
  • 4Morse MA, Garst J, Khan S, et al. Preliminary results of a phase I/II study of active immunotherapy with autologous dexosomes loaded with MAGE peptides in HLA A2+ patients with stage III/IV non-small cell lung cancer [J]. Proc Am Soc Oncol, 2002;21(1):42-51.
  • 5André F, Schartz N, Movassagh M, et al. Malignant effusions accumulate immunogenic tumor-derived exosomes: Novel source of tumor antigens and potential approach for cancer immunotherapy [J]. Lancet, 2002;360(9329):295-305.
  • 6Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles [J]. J Exp Med, 1996;183(3):1161-1172.

同被引文献28

  • 1Insug O,Ku G,Ertl HC,et al.A dendritic cell vaccine induces protective immunity to intracranial growth of glioma[J].Anticancer Res,2002,22:613-621.
  • 2Ryuya Y,Junpei H,Naoki Y,et al.Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma:Results of a clinical phase Ⅰ/Ⅱ Trial[J].Clin Cancer Res,2005,11(11):4160-4167.
  • 3Strome SE,Voss S,Wilcox R,et al.Strategies for antigen loading of dendritic cells to enhance the antitumor immune response[J].Cancer Res,2002,62(6):1884-1889.
  • 4Yamanaka R,Yajma N,Abe T,et al.Dendritic cell-based glioma immunotherapy[J].Int J Oncel,2003,(1):5-15.
  • 5Fecci PE,Mitchell DA,Archer GE,et al.The history,evolution and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors[J].J Neurooncol,2003,64(1 -2):161-167.
  • 6Cheever MA,Disis ML,Bernhard H,et al.Immunity to oncngenic proteins[J].Immunol Rev,1995,145:33-59.
  • 7Rosenherg SA.Cancer vaccines based on the identification of genes encoding cancer regression antigens[J].Immunol Today,1997,18 (4):175-182.
  • 8Cheever MA,Chen W.Therapy with cultured T cells:principles revisited[J].Immunol Rev,1997,157:177-194.
  • 9Restifo NP,Kawakami Y,Marincola F,et al.Molecular mechanisms used by tumors to escape immune recognition:immunogenetherapy and the cell biology of major histocompntibility complox class Ⅰ[J].J Immunother,1993,14(3):182-190.
  • 10Morse MA,Garst J,Khan S,et al.Preliminary results of a phase Ⅰ/Ⅱ study of active immunotherapy with autoiogeus dexesomes loaded with MAGE peptides in HLA A2 + patients with stage Ⅲ/Ⅳ non-small cell lung cancer[J].Proc Am Soc Oncol,2002,21 (1):42-51.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部